ciltacabtagene autoleucel,Pomalidomide,Bortezomib,Dexamethasone,Daratumumab,Daratumumab,Pomalidomide,Dexamethasone,Bortezomib,Ixazomib,Lenalidomide,Carfilzomib,Elotuzumab,idecabtagene vicleucel
Janssen,Bms,Janssen,takeda,AbbVie,2Seventy Bio
['cartitude-4', 'karmma', 'karmma-3', 'cartitude', 'abecma', 'carvykti', 'multiple myeloma', 'bms']
j&amp;j and legend's carvykti offered a 85% pfs benefit in triple class-refractory multiple myeloma patients, new cartitude-4 data show. the number was 54% in karmma-3 for bms' abecma #asco23 
Pharma’s go-to destination for news & trends shaping approved drugs. Delivering news, revealing insights straight to your inbox.